Q-omics provides the consensus-scored RAX profile across patient tissues and cancer cell-line models. RAX expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAX is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, RAX protein abundance shows 14,275 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, COAD, and PDAC as cancer lineages where RAX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAX survival associations across molecular data types. RAX RNA expression shows survival associations in the most cancer types (18), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAX RNA expression–survival associations across cancer types. High RAX expression shows unfavorable associations in KIRC, THCA, BLCA, UCEC, ACC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAX RNA expression.
This table summarizes RAX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RAX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAX shows higher tumor expression in COAD, LUSC, BRCA, KIRP, UCEC and KICH. The COAD box plot shows higher RAX RNA expression in tumor versus normal tissue (log2 FC = +0.018, t-test p = .001).
This table shows molecular features associated with RAX in patient tissues and cancer cell lines. In patient samples, RAX shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
